SOPHiA GENETICS Q3 2026 Earnings Call - SOPHIA GENETICS SA

Explicit Guidance:

• FY2026 Revenue: Expected to be at the upper end of the previously issued range of $94–$96 million.
• FY2026 Adjusted EBITDA: Reaffirmed guidance for a loss of $29–$32 million (vs. $41.5 million in FY2025).
• 2027 Outlook: Management expects to cross over to positive adjusted EBITDA in the second half of 2027.
• 2027 Revenue Visibility: Management states that 95% of 2027 revenue growth is already covered by bookings signed in 2026.

Business-Segment Outlook:

• U.S. Market: Growth is projected to continue; Q3 saw 41% revenue growth. New major accounts (North York, iGenomics, West Coast health system) scheduled to ramp significantly in Q4 2026 and into 2027. New signings (PathGroup, University of Arkansas) expected to expand over time.
• Liquid Biopsy: Volumes up >100% YoY in Q3. Expect continued ramp with 85+ institutions signed globally. Strategic investments in medical affairs (Europe, Asia, Latin America) to drive ex-U.S. adoption and clinical evidence generation.
• Solid Tumor: Optimistic about sustained or accelerated growth; new MSK ImpactFlex application gaining traction in community and academic labs due to cost efficiency (up to 50% cheaper than legacy panels) and superior detection of complex mutations (e.g., MTAP).
• Hematology: Confidence in sustaining growth rates; new comprehensive heme products and monitoring technologies (MRD, AML) driving innovation.
• Rare Disorders/Inherited: Continued volume growth expected; exome-to-genome transition creating opportunities. Large expansion deals (e.g., $2M/year rare disease expansion) expected to ramp into 2027.
• Biopharma: Transitioning to a growth accelerator. Current pipeline includes:
  • AstraZeneca: Two companion diagnostics (CDX) for prostate and blood cancer; test will incorporate Myriad Genetics' genomic instability score.
  • Top 10 Biopharma: New multimodal AI predictor for bladder cancer immunotherapy response (in development).
  • Pipeline: Net new business pipelines for clinical and biopharma businesses exceed $100 million.

Market and Competitive Outlook:

• U.S. Economic Dynamics: Reimbursement rates rising, denial rates improving, and sequencing costs dropping create favorable conditions for hospitals/labs to launch in-house testing.
• Competitive Landscape: Platform differentiators include "Collective Intelligence" AI learning from global data, cost-efficiency of complex panels, and superior accuracy in complex mutation detection compared to centralized and decentralized competitors.
• Global Expansion: EMEA outperforming with >200% growth in Norway and >100% in UK; Latin America (Brazil, Colombia) and Asia-Pacific (33% growth) showing strong momentum.
• Market Shift: Trend moving from "send-out" testing to in-house testing, driven by the value of retaining patient data and AI integration.

Macro / Industry Outlook:

• Foreign Exchange (FX): Headwinds from USD strength against the Euro and Swiss Franc (depreciation in September) expected to impact reported revenue in Q4 2026. Management assumes FX rates remain relatively stable rather than moving dramatically.
• Regulatory/Legal: U.S. litigation (Garden) remains a focus; UPC Paris rejected Garden's appeal and ordered them to pay legal fees, confirming no injunction on MSK Access commercialization. UK proceedings partially discontinued but remain pending.
• Technology Trends: Shift toward multi-modal AI (genomic, radiomic, clinical) and whole-genome sequencing in rare disorders.

Strategic Initiatives:

• Commercial Expansion: Selective headcount additions in North America (Sales/Marketing) and ex-U.S. Medical Affairs to support liquid biopsy education and adoption.
• Product Launches: Continued rollout of MSK ImpactFlex and MSK Access (liquid biopsy) to new institutions globally.
• AI & Data Strategy: Leveraging 118,000+ monthly analyses to train AI; building "Collective Intelligence" as a moat.
• M&A/Partnerships: Focus on strategic collaborations with top biopharma companies for CDX development and real-world evidence generation.

Risks and Headwinds to Outlook:

• Foreign Exchange: Continued USD strength could suppress reported revenue figures in Q4.
• Litigation: Remaining UK infringement claims against Garden remain pending.
• Implementation Timelines: Customer ramp-up typically takes 6–9 months; delays in validation or adoption could impact immediate revenue recognition.
• Reimbursement/Regulatory: While improving, reimbursement dynamics and regulatory approvals remain critical for market expansion.
• Market Competition: Intensifying competition in solid tumor and rare disease spaces, particularly from legacy players and new entrants.

Management Tone on the Future:

• Confidence Level: High confidence in revenue growth sustainability and profitability trajectory.
• Growth Rate: Expects to maintain >20–25% revenue growth and drop nearly 60% of incremental revenue to the bottom line.
• Cost Discipline: Committed to profitable growth with flat headcount in many areas (leveraging AI) while selectively investing in high-upside markets (US commercial, ex-U.S. liquid biopsy).
• Trend: Shift from "growth at all costs" to "profitable growth," with strong operating leverage driving margin expansion.

Miscellaneous:

• Backlog: Remains high; 2027 growth visibility is strong due to 95% of projected growth already booked.
• Customer Retention: Net dollar retention of 118%; annualized churn <1%.
• Legal Costs: Approximately $931,000 incurred in Q3 for Garden litigation, included in adjusted EBITDA reconciliation.